Ben Begasse Jr., Concentric Healthcare
The model the industry and the agencies have operated under is broken. I've had phone calls over the last three weeks from both biologic and traditional pharma clients. And all of them were looking for effectiveness in their marketing strategies. And in every case digital was a part of that thinking, whether it was digital to the patient, digital to the physician, or even digital to their sales reps. I believe healthcare's going to be almost 100 percent digital in five years.
The model the industry and the agencies have operated under is broken. I've had phone calls over the last three weeks from both biologic and traditional pharma clients. And all of them were looking for effectiveness in their marketing strategies. And in every case digital was a part of that thinking, whether it was digital to the patient, digital to the physician, or even digital to their sales reps. I believe healthcare's going to be almost 100 percent digital in five years.
Sales reps are not an effective reach and frequency medium. The dramatic rise in the sales force size, and the importance of call frequency, took the quality out of the communication between the sales representative and the physician. It hurt the relationship. And it had very little boost in return on marketing, only a 10 percent increase in sales.
A great job is initially done training reps on disease states and product information and competitive products, but follow-up education falls short. It's not budgeted in. With the Internet, you can help increase the effectiveness of the sales force through continued tutelage on application: application of their medical knowledge; application of what they know their customer needs are. They would know then how and what resources could be used—a financial aid package or a risk management practice or even a patient program. If they did that, then you'd see the relationships between physicians and sales reps improve because it would be based on credibility, merit, and trust.
Pharma marketers have a plethora of data that either they don't know how to analyze or sift through, or they're restricted in doing so. They're not utilizing that data to provide a more customized, personal communication with those individual people. Whenever we're able to wrestle data away from a client, we find some type of trend to wrap a strategy around, and that ultimately propels the product forward. Everyone is very enamored of strategy, but it's how that strategy manifests in the form of tactical execution that makes it smart.
The skinny
Concentric Healthcare is an independent agency with five operating units. Pictured: Michael Sanzen, CCO; Ken Begasse Sr., CEO; Michael Devlin, executive VP, managing director of consumer; and Ken Begasse Jr., CEO.
Telephone: 212-633-9700
E-mail: info@concentric-rx.com
Web site: concentric-rx.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
